STOCK TITAN

Equillium, Inc. - EQ STOCK NEWS

Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.

Equillium, Inc. (EQ) is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing innovative therapies for autoimmune and inflammatory disorders with significant unmet medical needs. Founded in 2017, Equillium has quickly established itself as a frontrunner in the biopharmaceutical industry through its focus on novel treatments that modulate the immune system.

The company’s primary product candidate is itolizumab, a unique monoclonal antibody targeting the immune checkpoint receptor CD6. Itolizumab is currently in advanced clinical trials, specifically a Phase 1b/2 trial for the treatment of acute graft-versus-host disease (aGVHD) and a Phase 1 trial for asthma and lupus nephritis. This promising treatment has shown potential in modulating immune responses and reducing inflammation, providing hope for patients suffering from severe autoimmune conditions.

In addition to itolizumab, Equillium's pipeline includes other groundbreaking therapies. EQ101 is a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15. EQ101 is Phase 2-ready and is expected to begin patient enrollment for an alopecia areata study in the second half of 2022. Another noteworthy drug is EQ102, a cytokine inhibitor that targets IL-15 and IL-21, which is also ready for clinical development and will soon begin enrolling patients in a Phase 1 trial, including those with celiac disease.

Equillium’s commitment to addressing immuno-inflammatory disorders is further demonstrated through its strategic partnerships and collaborations. These alliances have enabled the company to enhance its research capabilities, expedite clinical trials, and bring novel treatments to market more efficiently.

Financially, Equillium is well-positioned to continue its research and development activities. The company has secured funding through various channels, ensuring the advancement of its clinical programs. By focusing on diseases with high unmet needs and leveraging its unique approach to immune modulation, Equillium aims to deliver impactful therapies that improve patient outcomes and quality of life.

For the latest updates on Equillium, Inc., including recent achievements and ongoing projects, keep an eye on their official communications and news releases.

Rhea-AI Summary

Equillium Inc (Nasdaq: EQ), a clinical-stage biotech company, has announced its estimated Q2 2024 financial position. The company's cash, cash equivalents, and short-term investments totaled approximately $33.3 million at the end of Q2, marking an increase of about $1.0 million from Q1 2024. This increase is primarily attributed to a $2.7 million tax credit received from the Australian tax authority for 2023 R&D expenses.

Equillium plans to release its complete Q2 2024 financial results around August 8. The company emphasizes that these figures are preliminary and subject to final adjustments. The data has not been audited or reviewed by an independent accounting firm and should not be considered a substitute for official financial statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
-
Rhea-AI Summary

Equillium (Nasdaq: EQ), a clinical-stage biotech firm focused on autoimmune and inflammatory disorders, will participate in two upcoming investor conferences in July. The Leerink Partners Therapeutic Forum in Boston on July 9-10 will feature one-on-one investor meetings and panel presentations on inflammation and immunology.

Additionally, Equillium will present at the JonesTrading Healthcare Seaside Summit on July 15 at Alila Marea Beach Resort in Encinitas, California. This event will include a corporate presentation on the company's clinical programs and partnership with Ono Pharmaceutical, along with investor meetings. The presentation will be available via webcast on Equillium's website, with an archived replay accessible for 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Equillium (Nasdaq: EQ), a clinical-stage biotech firm, announced its expected inclusion in the Russell Microcap Index effective July 1, 2024. This follows the Russell annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization. Membership in this index lasts a year and also includes growth and value style indexes. CEO Bruce Steel noted that this will increase Equillium's exposure, benefiting from its recent Phase 2 data on EQ101 for alopecia areata and its partnership with Ono Pharmaceutical.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
none
Rhea-AI Summary

Equillium announced on May 31, 2024, that its Compensation Committee granted a nonstatutory stock option award to a new employee under the company's 2024 Inducement Plan. This inducement award, approved under Nasdaq Listing Rule 5635(c)(4), consists of 7,200 shares of common stock with an exercise price of $1.50 per share, which matches the closing stock price on May 31, 2024. The vesting schedule for this award spans four years, with 25% vesting after one year and the remainder vesting monthly over the next three years, contingent on the employee's continued service with Equillium.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.87%
Tags
none
-
Rhea-AI Summary

Equillium announced positive topline data from a Phase 2 study of EQ101 in treating alopecia areata (AA), an autoimmune disease causing hair loss. The study indicated favorable safety and tolerability with no serious adverse events (SAEs). Results showed 20% of subjects who completed 24 weeks of treatment reached a SALT score ≤ 20, improving from a baseline SALT of 35 to 100. Among those with moderate to severe AA, 29% achieved a SALT score ≤ 20. EQ101, a multi-cytokine inhibitor targeting IL-2, IL-9, and IL-15, demonstrated promising efficacy, warranting further development and exploration in other dermatological conditions like vitiligo and atopic dermatitis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.89%
Tags
-
Rhea-AI Summary

Equillium (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the Jefferies Global Healthcare Conference from June 4-6, 2024, in New York. The presentation, scheduled for June 5 at 10:30 am ET, will cover the company's clinical programs, including EQ101 for alopecia areata, with data expected by the end of June 2024. The firm will also discuss its partnership with Ono Pharmaceutical and its 2024 milestones. Management will be available for one-on-one meetings. The presentation will be webcast live and available for replay for 90 days on Equillium's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
conferences
Rhea-AI Summary

Equillium (Nasdaq: EQ) has surpassed the interim enrollment target in its Phase 3 EQUATOR study of itolizumab for acute graft-versus-host disease (aGVHD). Over 100 patients from more than 100 clinical trial sites in 12 countries are participating. Interim data will be reviewed by an independent data monitoring committee in Q3, which will trigger a three-month option exercise period for Ono Pharmaceutical to acquire rights to itolizumab. If exercised, Ono will pay Equillium approximately $32.2 million, with potential milestone payments of up to $101.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Equillium Inc. (Nasdaq: EQ) reported a $32.3 million cash balance in Q1 2024, expected to last until 2H 2025. Positive data from the Phase 1b EQUALISE study of itolizumab in lupus nephritis patients was released. Anticipated milestones include EQ101 Phase 2 study results in Q2 2024 and EQUATOR acute graft-versus-host disease interim review in Q3 2024. Financially, revenue was $10.7 million, with $9.7 million in R&D expenses and $3.7 million in G&A expenses. Net loss was $2.7 million, with $32.3 million in cash, cash equivalents, and short-term investments as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15%
Tags
-
Rhea-AI Summary

Equillium, Inc. (Nasdaq: EQ) presented a poster at the annual meeting of The American Association of Immunologists showcasing the role of CD6 in cell adhesion and migration, highlighting the efficacy of itolizumab in preventing trans-endothelial migration of effector T cells. The data revealed the mechanism of action of itolizumab and its ability to modulate T cell activity and trafficking, offering insights into treating autoimmune and inflammatory disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
none
Rhea-AI Summary
Equillium, Inc. granted an inducement award of 10,000 nonstatutory stock options to a new employee under its 2024 Inducement Plan. The stock option has an exercise price of $2.11 per share, vesting over four years. This award aims to incentivize the new employee's continued service relationship with Equillium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
none

FAQ

What is the current stock price of Equillium (EQ)?

The current stock price of Equillium (EQ) is $0.68 as of December 5, 2024.

What is the market cap of Equillium (EQ)?

The market cap of Equillium (EQ) is approximately 24.1M.

What does Equillium, Inc. specialize in?

Equillium, Inc. specializes in developing therapies for autoimmune and inflammatory disorders with significant unmet medical needs.

What is itolizumab?

Itolizumab is Equillium's primary product candidate, a monoclonal antibody targeting the CD6 immune checkpoint receptor, currently in Phase 1b/2 trials for aGVHD and Phase 1 trials for asthma and lupus nephritis.

What other products are in Equillium's pipeline?

Equillium's pipeline includes EQ101, a cytokine inhibitor targeting IL-2, IL-9, and IL-15, and EQ102, which targets IL-15 and IL-21, both aimed at treating various autoimmune disorders.

Where is Equillium, Inc. headquartered?

Equillium, Inc. is headquartered in La Jolla, California.

When was Equillium, Inc. founded?

Equillium, Inc. was founded in 2017.

What are the current clinical trials for itolizumab?

Itolizumab is currently in Phase 1b/2 clinical trials for acute graft-versus-host disease and Phase 1 trials for asthma and lupus nephritis.

What is the focus of EQ101?

EQ101 is a first-in-class cytokine inhibitor targeting IL-2, IL-9, and IL-15, expected to begin a Phase 2 study for alopecia areata.

What conditions is EQ102 targeting?

EQ102 targets IL-15 and IL-21 and is expected to begin a Phase 1 trial for conditions including celiac disease.

How is Equillium funded?

Equillium secures funding through various channels to support its research and development activities, ensuring the advancement of its clinical programs.

How can I stay updated on Equillium, Inc.'s latest news?

To stay updated on Equillium, Inc.'s latest news and developments, follow their official communications and news releases.

Equillium, Inc.

Nasdaq:EQ

EQ Rankings

EQ Stock Data

24.09M
22.50M
36.21%
20.04%
0.33%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA